On Sept. 24, 2026, Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults with type 2 diabetes. Onswik is designed to deliver steady basal insulin levels over a full seven days.

The FDA approval is based on data from the QWINT Phase 3 clinical trials, which evaluated the safety and efficacy of once-weekly Onswik in over 3,400 adults with type 2 diabetes. In each QWINT trial, once-weekly Onswik met the primary endpoint of non-inferior A1C reduction from baseline that was comparable to insulin glargine U-100 (glargine) or insulin degludec U-100 (degludec).

In these clinical trials, Onswik demonstrated an overall safety profile similar to the daily basal insulins studied. Onswik should not be used by people who have type 1 diabetes due to increased risk of severe hypoglycemia (low blood sugar). Common side effects of Onswik include low blood sugar, allergic reactions, reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of hands and feet, and weight gain.

Around one in eight Americans live with diabetes, and most of them have type 2 diabetes. Globally by 2030, over 510 million people are expected to live with the disease and 38 million of these are expected to use insulin. Insulin remains an important treatment option for many people with type 2 diabetes who do not achieve glycemic goals with other therapies.

The Onswik™ KwikPen^® will be available in the U.S. in the coming months in two concentrations: 500 units/mL (contains 1,500 units total) and 1,000 units/mL (contains 3,000 units total).